Controlled release systems and low dose androgens
US5629303A · kind A · utility
24Cited by
18References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 3, 1995 |
| Grant date | May 13, 1997 |
| Priority date | — |
| Expiry date | Mar 3, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T428/2982
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treatment and prevention of estrogen-related diseases, and of fertility control, include low dose (e.g. less than 50 nanomolar serum concentration)administration of certain anabolic steroids, progestins and other substantially non-masculinizing androgenic compounds. Sustained release formulations substantially free of organic solvent, and sustained release formulations for maintaining low serum levels of androgen are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.